Aviragen Therapeutics to Host Conference Call to Report Second Quarter Fiscal Year 2017 Financial Results on February 2, 2017...
January 26 2017 - 04:01PM
Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company
that is developing the next generation of antivirals, today
announced that management will host a conference call on Thursday,
February 2, 2017 at 4:30 p.m. ET to review the Company’s financial
results for the three month period ended December 31, 2016 and will
provide an update on recent corporate developments. The Company
will issue a press release summarizing its financial results the
same day, prior to the conference call.
In order to participate in the conference call, please dial
(877) 312-5422 (domestic) or (253) 237-1122 (international) and
refer to conference ID number 60561525. The live webcast can be
accessed under the Investors section of the Company’s website at
www.aviragentherapeutics.com.
About Aviragen Therapeutics,
Inc.
Aviragen Therapeutics is focused on the discovery and
development of the next generation of direct-acting antivirals to
treat infections that have limited therapeutic options and affect a
significant number of patients globally. The Company has four Phase
2 clinical programs: vapendavir, an oral treatment for rhinovirus
(RV) upper respiratory infections in moderate-to-severe asthmatics;
vapendavir is also being evaluated for the treatment of RV
infections in hematopoietic stem cell transplant patients; BTA585,
an oral fusion protein inhibitor in development for the treatment
of respiratory syncytial virus infections; and BTA074, a topical
antiviral treatment for condyloma caused by human papillomavirus
types 6 & 11. For additional information about the Company,
please visit www.aviragentherapeutics.com.
Contacts:
Mark Colonnese
Executive Vice President and Chief Financial Officer
Aviragen Therapeutics, Inc.
(678) 221-3381
mcolonnese@aviragentherapeutics.com
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2023 to Mar 2024